Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy | Zendy

Feng Xu | Zendy; Jiexin Chen | Zendy; Yang Xiongbin | Zendy; Xin-Bin Hong | Zendy; Zixiong Li | Zendy; Ling Lin | Zendy; Yongsong Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy

Author(s) -

Feng Xu,

Jiexin Chen,

Yang Xiongbin,

Xin-Bin Hong,

Zixiong Li,

Ling Lin,

Yongsong Chen

Publication year - 2020

Publication title -

molecular therapy — oncolytics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.424

H-Index - 23

ISSN - 2372-7705

DOI - 10.1016/j.omto.2020.03.021

Subject(s) - lung cancer , adenocarcinoma , immune system , medicine , oncology , cancer , cancer therapy , immunology

Lung cancer is the most common cause of cancer deaths worldwide, and lung adenocarcinoma (LUAD) is the most common histological subtype. However, the prognostic and predictive outcomes differ because of this cancer type heterogeneity. LUAD subtypes were identified on the basis of the immunogenomic profiling of 29 immune signatures. We named three LUAD subtypes: Immunity High, Immunity Medium, and Immunity Low. The Immunity High subtype was characterized by immune activation, e.g., increased immune scores, elevated stromal scores and the highest infiltration of CD8 + T cells, and decreased tumor purities. Activated expressions of human leukocyte antigen (HLA) genes, immune checkpoint molecules, and T helper 1 (Th1)/interferon-gamma (IFNγ) gene signature were also observed in the Immunity High subtype. N 6 -methyladenosine (m 6 A) RNA methylation, associated with cancer initiation and progression, was reduced in the Immunity High subtype. Functional and signaling pathway enrichment analysis further showed that differentially expressed genes between the Immunity High subtype and the other subtypes mainly participated in immune response and some cancer-associated pathways. In addition, the Immunity High subtype exhibited more sensitivity to immunotherapy and chemotherapy. Finally, candidate compounds that aimed at LUAD subtype differentiation were identified. Comprehensively characterizing the LUAD subtypes based on immune signatures may help to provide potential strategies for LUAD treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research